What are the limits to biomedical research acceleration through general-purpose AI?

Checked 30 Sept 2026. Open license (CC-BY, CC-BY-SA, CC0, public domain): full text indexed and used in synthesis.

Although general-purpose artificial intelligence (GPAI) is widely expected to accelerate scientific discovery, its practical limits in biomedicine remain unclear. We assess this potential by developing a framework of GPAI capabilities across the biomedical research lifecycle. Our scoping literature review indicates that current GPAI could deliver a speed increase of around 2x, whereas future GPAI could facilitate strong acceleration of up to 25x for physical tasks and 100x for cognitive tasks. However, achieving these gains may be severely limited by factors such as irreducible biological constraints, research infrastructure, data access, and the need for human oversight. Our expert elicitation with eight senior biomedical researchers revealed skepticism regarding the strong acceleration of tasks such as experiment design and execution. In contrast, strong acceleration of manuscript preparation, review and publication processes was deemed plausible. Notably, all experts identified the assimilation of new tools by the scientific community as a critical bottleneck. Realising the potential of GPAI will therefore require more than technological progress; it demands targeted investment in shared automation infrastructure and systemic reforms to research and publication practices.

• Hebenstreit et al. 2026 synthesize four existing autonomy frameworks into a biomedical-specific framework that distinguishes cognitive from physical capabilities. Within that framing, they estimate that general-purpose AI agents combined with continuously operating self-driving laboratories could shrink research project timelines from years to months or weeks. Trace →

• AI for science and agentic research